STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
This study is currently recruiting participants.
Verified June 2013 by University Hospital Heidelberg
Sponsor:
Mathias Witzens-Harig
Collaborators:
Johannes Gutenberg University Mainz
Technische Universität München
Ludwig-Maximilians - University of Munich
University Hospital Ulm
University Hospital Erlangen
Charite University, Berlin, Germany
University Hospital Freiburg
Johann Wolfgang Goethe University Hospitals
Information provided by (Responsible Party):
Mathias Witzens-Harig, University Hospital Heidelberg
ClinicalTrials.gov Identifier:
NCT01653067
First received: July 17, 2012
Last updated: June 11, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | July 2018 |
| Estimated Primary Completion Date: | June 2018 (Final data collection date for primary outcome measure) |